Blog Archive
-
▼
2007
(90)
-
▼
December
(6)
- Panacea Pharmaceuticals' Lung Cancer Diagnostic Te...
- Infinity and Medimmune, Phase 2 Trial of IPI-504 t...
- Theravance, GSK1160724, Phase 1 Clinical Study Wit...
- Discovery Labs, Aerosurf Improves Lung Function a...
- Rigel , Initiation of Phase 1 Clinical Trial of R...
- IDM Pharma, IDM-2101 Updated Phase 2 Results Show ...
-
▼
December
(6)
Dec 15, 2007
Discovery Labs, Aerosurf Improves Lung Function and Reduces Inflammation in a Model of Respiratory Distress Syndrome
December 3, 2007 — ...Aerosurf is an aerosolized formulation of Discovery Lab’s novel KL4 surfactant technology that is delivered non-invasively via novel aerosol generating technology and employs nasal continuous positive airway pressure (nCPAP). Aerosurf, like Discovery’s lead product Surfaxin®, is a precisionengineered synthetic, peptide-containing surfactant which is designed to closely mimic the essential attributes of human lung surfactant.... Discovery Labs' PDF -